{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Galsky MD"],"funding":["NCI NIH HHS","F Hoffman-La Roche, Ltd"],"pagination":["476-486"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11962399"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples using the SP142 and 22C3 assays from the phase III IMvigor130 trial and found discordant findings summarized by four phenotypes: PD-L1 positive by both assays, PD-L1 positive by the SP142 assay only, PD-L1 positive by the 22C3 assay only, and PD-L1 negative by both assays double negative. PD-L1 positive by both assays and PD-L1 positive by the SP142 assay only urothelial cancers were associated with more favorable ICB outcomes and increased dendritic cell (DC) infiltration. SP142 PD-L1 staining co-localized with DC-LAM"],"journal":["Cancer immunology research"],"pubmed_title":["Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer."],"pmcid":["PMC11962399"],"funding_grant_id":["2016274","T32 CA078207"],"pubmed_authors":["Izadmehr S","Kikuchi E","Mellman I","Koeppen H","David JM","Bernhard S","Davis ID","Rishipathak D","Anker JF","Johnston RJ","Grande E","Gupta S","Van Elzen R","De Santis M","Banchereau R","Sanjabi S","Gnjatic S","Mariathasan S","Galsky MD","Yuen K","Bamias A","Peterson M","Roels J","Arranz JA","Guan X","Kockx M","Williams P"],"additional_accession":[]},"is_claimable":false,"name":"Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.","description":"Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples using the SP142 and 22C3 assays from the phase III IMvigor130 trial and found discordant findings summarized by four phenotypes: PD-L1 positive by both assays, PD-L1 positive by the SP142 assay only, PD-L1 positive by the 22C3 assay only, and PD-L1 negative by both assays double negative. PD-L1 positive by both assays and PD-L1 positive by the SP142 assay only urothelial cancers were associated with more favorable ICB outcomes and increased dendritic cell (DC) infiltration. SP142 PD-L1 staining co-localized with DC-LAM","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T18:08:47.249Z","creation":"2025-07-01T03:05:28.645Z"},"accession":"S-EPMC11962399","cross_references":{"pubmed":["39853278"],"doi":["10.1158/2326-6066.CIR-24-0649"]}}